On June 18, 2025, Telomir Pharmaceuticals announced promising preclinical results for their drug, Telomir-1, which showed improved cell health in progeria cells, suggesting potential to address a rare genetic disorder that causes rapid aging in children. The findings highlight restoration of cell viability and function in challenging conditions, paving the way for future clinical development.